{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:28:16Z","timestamp":1792297696430,"version":"4.4.0"},"reference-count":219,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2253,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1002\/hep.22906","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T18:29:42Z","timestamp":1234376982000},"page":"291-308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1051,"title":["Primary biliary cirrhosis # \u2020"],"prefix":"10.1097","volume":"50","author":[{"given":"Keith D.","family":"Lindor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora V.","family":"Bergasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-31-20241201","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0016-5085(95)90469-7","article-title":"Position and policy statement: American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers.","volume":"108","year":"1995","journal-title":"Gastroenterology"},{"key":"R4-31-20241201","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells.","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol Rev"},{"key":"R5-31-20241201","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis.","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-31-20241201","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment.","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"R7-31-20241201","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-3083.1994.tb03346.x","article-title":"Major histocompatibility complex classII alleles in primary biliary cirrhosis.","volume":"39","author":"Zhang","year":"1994","journal-title":"Scand J Immunol"},{"key":"R8-31-20241201","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interviewbased study of 1032 patients.","volume":"42","author":"Gershwin","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R9-31-20241201","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hep.21076","article-title":"Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites.","volume":"43","author":"Ala","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R10-31-20241201","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.179.4.2651","article-title":"Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization.","volume":"179","author":"Leung","year":"2007","journal-title":"J Immunol"},{"key":"R11-31-20241201","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.161.10.5157","article-title":"Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis.","volume":"161","author":"Migliaccio","year":"1998","journal-title":"J Immunol"},{"key":"R12-31-20241201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1172\/JCI200110716","article-title":"Bcl2dependent oxidation of pyruvate dehydrogenaseE2, a primary biliary cirrhosis autoantigen, during apoptosis.","volume":"108","author":"Odin","year":"2001","journal-title":"J Clin Invest"},{"key":"R13-31-20241201","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis.","volume":"138","author":"Gershwin","year":"1987","journal-title":"J Immunol"},{"key":"R14-31-20241201","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.510230307","article-title":"Epitope mapping and reactivity of autoantibodies to the E2 component of 2oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2oxoglutarate dehydrogenase complex.","volume":"23","author":"Moteki","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R15-31-20241201","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1053\/jhep.2000.19254","article-title":"Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine.","volume":"32","author":"Tanaka","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R16-31-20241201","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.21583","article-title":"A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMAnegative primary biliary cirrhosis.","volume":"45","author":"Oertelt","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R17-31-20241201","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDCE2specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.","volume":"109","author":"Kita","year":"2002","journal-title":"J Clin Invest"},{"key":"R18-31-20241201","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI4213","article-title":"Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis.","volume":"102","author":"Shimoda","year":"1998","journal-title":"J Clin Invest"},{"key":"R19-31-20241201","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/hep.21871","article-title":"Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom.","volume":"46","author":"Corpechot","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R20-31-20241201","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0168-8278(99)80097-X","article-title":"Familiar primary biliary cirrhosis reassessed: a geographicallybased population study.","volume":"30","author":"Jones","year":"1999","journal-title":"J Hepatol"},{"key":"R21-31-20241201","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural history of early primary biliary cirrhosis.","volume":"348","author":"Metcalf","year":"1996","journal-title":"Lancet"},{"key":"R22-31-20241201","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in healthy adults.","volume":"27","author":"Mattalia","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R23-31-20241201","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0016-5085(77)80011-5","article-title":"Presentation and course of asymptomatic primary biliary cirrhosis.","volume":"72","author":"Long","year":"1977","journal-title":"Gastroenterology"},{"key":"R24-31-20241201","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.","volume":"20","author":"Mahl","year":"1994","journal-title":"J Hepatol"},{"key":"R25-31-20241201","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(90)90968-7","article-title":"Symptom development and prognosis in primary biliary cirrhosis: a study in two centers.","volume":"99","author":"Mitchison","year":"1990","journal-title":"Gastroenterology"},{"key":"R26-31-20241201","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00365528909092240","article-title":"Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease.","volume":"24","author":"Nyberg","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"R27-31-20241201","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: followup for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R28-31-20241201","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis.","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R29-31-20241201","first-page":"1166","article-title":"Association between fatigue and decreased survival in primary biliary cirrhosis.","volume":"56","author":"Newton","year":"2007","journal-title":"Gut"},{"key":"R30-31-20241201","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0016-5085(86)90972-8","article-title":"Azathioprine and prognosis in primary biliary cirrhosis.","volume":"90","author":"Christensen","year":"1986","journal-title":"Gastroenterology"},{"key":"R31-31-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis.","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"R32-31-20241201","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.","volume":"32","author":"Corpechot","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R33-31-20241201","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis.","volume":"23","author":"Locke","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R34-31-20241201","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"key":"R35-31-20241201","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Longterm ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.","volume":"29","author":"Angulo","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R36-31-20241201","first-page":"759","article-title":"A randomized, doubleblind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R37-31-20241201","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Doubleblind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"19","author":"Heathcote","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R38-31-20241201","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"key":"R39-31-20241201","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent longterm survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R40-31-20241201","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCAPBC Study Group.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R41-31-20241201","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the longterm treatment of primary biliary cirrhosis. The UDCAPBC Study Group.","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"R42-31-20241201","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R43-31-20241201","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Tenyear survival in ursodeoxycholic acidtreated patients with primary biliary cirrhosis. The UDCAPBC Study Group.","volume":"29","author":"Poupon","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R44-31-20241201","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"key":"R45-31-20241201","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebocontrolled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"key":"R46-31-20241201","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"R47-31-20241201","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodioltreated patients.","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"R48-31-20241201","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"R49-31-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R50-31-20241201","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.1840100516","article-title":"Extramural crossvalidation of the Mayo primary biliary cirrhosis survival model establishes its generalizability.","volume":"10","author":"Grambsch","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R51-31-20241201","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCAtreated patients with primary biliary cirrhosis.","volume":"24","author":"Corpechot","year":"2004","journal-title":"Liver Int"},{"key":"R52-31-20241201","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(99)80098-1","article-title":"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCAPBC Group.","volume":"30","author":"Poupon","year":"1999","journal-title":"J Hepatol"},{"key":"R53-31-20241201","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.","volume":"194","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"key":"R54-31-20241201","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Antigp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis.","volume":"45","author":"Nakamura","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R55-31-20241201","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.","volume":"29","author":"Degott","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R56-31-20241201","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis.","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R57-31-20241201","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.21151","article-title":"Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.","volume":"43","author":"Corpechot","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R58-31-20241201","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1053\/gast.2002.32993","article-title":"The true impact of fatigue in primary biliary cirrhosis: a population study.","volume":"122","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"R59-31-20241201","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"R60-31-20241201","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/gut.2003.016766","article-title":"Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels.","volume":"53","author":"Forton","year":"2004","journal-title":"Gut"},{"key":"R61-31-20241201","doi-asserted-by":"crossref","first-page":"628A","DOI":"10.1002\/hep.21230","article-title":"Modafinil is effective treatment for excessive daytime somnolence and fatigue in primary biliary cirrhosis. Abstract.","volume":"44","author":"Newton","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R62-31-20241201","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis.","volume":"40","author":"Poupon","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R63-31-20241201","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.2005.080317","article-title":"Four year follow up of fatigue in a geographically defined primary biliary cirrhosis cohort.","volume":"55","author":"Jones","year":"2006","journal-title":"Gut"},{"key":"R64-31-20241201","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.1840400434","article-title":"Primary biliary cirrhosis: Report of a focus group.","volume":"40","author":"Bergasa","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R65-31-20241201","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2007.01.036","article-title":"Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis.","volume":"46","author":"van Os","year":"2007","journal-title":"J Hepatol"},{"key":"R66-31-20241201","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/BF01311724","article-title":"Increased incidence of hypothyroidism in primary biliary cirrhosis.","volume":"28","author":"Elta","year":"1983","journal-title":"Dig Dis Sci"},{"key":"R67-31-20241201","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis.","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R68-31-20241201","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis.","volume":"7","author":"Pares","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R69-31-20241201","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","article-title":"Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus.","volume":"73","author":"Ghent","year":"1977","journal-title":"Gastroenterology"},{"key":"R70-31-20241201","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.1840110526","article-title":"The pruritus of cholestasis: from bile acids to opiod antagonists.","volume":"11","author":"Jones","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R71-31-20241201","first-page":"152","article-title":"Longterm outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis.","volume":"30","author":"Ng","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R72-31-20241201","first-page":"467","article-title":"Variceal bleeding is associated with reduced risk of severe cholestasis in primary biliary cirrhosis.","volume":"71","author":"Thornton","year":"1989","journal-title":"Q J Med"},{"key":"R73-31-20241201","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0016-5085(92)90771-P","article-title":"Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis.","volume":"102","author":"Colina","year":"1992","journal-title":"Gastroenterology"},{"key":"R74-31-20241201","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep.1840200617","article-title":"Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis.","volume":"20","author":"Boyer","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R75-31-20241201","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1089-3261(03)00097-7","article-title":"Management of osteoporosis, fatsoluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis.","volume":"7","author":"Levy","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R76-31-20241201","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0016-5085(00)70423-9","article-title":"Vitamin Dreceptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis.","volume":"118","author":"Springer","year":"2000","journal-title":"Gastroenterology"},{"key":"R77-31-20241201","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.","volume":"35","author":"Menon","year":"2001","journal-title":"J Hepatol"},{"key":"R78-31-20241201","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are major risk factors for osteoporosis in primary biliary cirrhosis.","volume":"42","author":"Guanabens","year":"2005","journal-title":"J Hepatol"},{"key":"R79-31-20241201","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2796.2002.01066.x","article-title":"Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and wellpreserved liver function.","volume":"252","author":"Ormarsdottir","year":"2002","journal-title":"J Intern Med"},{"key":"R80-31-20241201","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2036.2004.02089.x","article-title":"Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls.","volume":"20","author":"BoultonJones","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R81-31-20241201","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-103-6-855","article-title":"Bone loss and reduced osteoblast function in primary biliary cirrhosis.","volume":"103","author":"Hodgson","year":"1985","journal-title":"Ann Intern Med"},{"key":"R82-31-20241201","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1172\/JCI117959","article-title":"Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.","volume":"95","author":"Janes","year":"1995","journal-title":"J Clin Invest"},{"key":"R83-31-20241201","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0016-5085(88)80029-5","article-title":"Fatsoluble vitamin nutriture in primary biliary cirrhosis.","volume":"95","author":"Kaplan","year":"1988","journal-title":"Gastroenterology"},{"key":"R84-31-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0016-5085(82)80291-6","article-title":"Osteoporosis in primary biliary cirrhosis: effects of 25hydroxyvitamin D3 treatment.","volume":"83","author":"Matloff","year":"1982","journal-title":"Gastroenterology"},{"key":"R85-31-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.1840140215","article-title":"Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis.","volume":"14","author":"Eastell","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R86-31-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9150(94)90006-X","article-title":"Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis.","volume":"105","author":"Gregory","year":"1994","journal-title":"Atherosclerosis"},{"key":"R87-31-20241201","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"R88-31-20241201","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","article-title":"Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as alltered cholesterol esterification.","volume":"89","author":"Jahn","year":"1985","journal-title":"Gastroenterology"},{"key":"R89-31-20241201","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis.","volume":"15","author":"Crippin","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R90-31-20241201","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"key":"R91-31-20241201","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.1840050522","article-title":"Pathogenesis of steatorrhea in primary biliary cirrhosis.","volume":"5","author":"Lanspa","year":"1985","journal-title":"HEPATOLOGY"},{"key":"R92-31-20241201","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fatsoluble vitamin levels in patients with primary biliary cirrhosis.","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R93-31-20241201","first-page":"2059","article-title":"Plasma vitaminK1 level is decreased in primary biliary cirrhosis.","volume":"92","author":"Kowdley","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R94-31-20241201","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0016-5085(81)90491-1","article-title":"Effect of 25hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis.","volume":"81","author":"Kaplan","year":"1981","journal-title":"Gastroenterology"},{"key":"R95-31-20241201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0168-8278(87)80539-1","article-title":"Vitamin E deficiency and its clinical significance in adults with.","volume":"4","author":"Jeffrey","year":"1987","journal-title":"J Hepatol"},{"key":"R96-31-20241201","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hep.1840090403","article-title":"Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal.","volume":"9","author":"Munoz","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R97-31-20241201","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1084\/jem.167.6.1791","article-title":"The autoepitope of the 74 kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyl transferase.","volume":"167","author":"Van de Water","year":"1988","journal-title":"J Exp Med"},{"key":"R98-31-20241201","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gut.35.2.260","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.","volume":"35","author":"Micheletti","year":"1994","journal-title":"Gut"},{"key":"R99-31-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00000478-199401000-00009","article-title":"Primary autoimmune cholangitis: an alternative to antimitochondrial antibodynegative primary biliary cirrhosis.","volume":"18","author":"Taylor","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"R100-31-20241201","first-page":"247","article-title":"Antimitochondrial antibodynegative primary biliary cirrhosis.","volume":"90","author":"Lacerda","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"R101-31-20241201","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibodypositive and negative primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R102-31-20241201","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jhep.2001.26514","article-title":"Detection of antimitochondrial autoantibodies in immunofluorescence negative patients with primary biliary cirrhosis using recombinant autoantigens.","volume":"34","author":"Miyakawa","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R103-31-20241201","first-page":"1440","article-title":"Abnormal expression of PDCE2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibodynegative primary biliary cirrhosis.","volume":"22","author":"Tsuneyama","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R104-31-20241201","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2188\/jea.16.30","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid.","volume":"16","author":"Sakauchi","year":"2006","journal-title":"J Epidemiol"},{"key":"R105-31-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2036.2003.01381.x","article-title":"Review article: is there an optimal therapeutic regimen for antimitochondrial antibodynegative primary biliary cirrhosis (autoimmune cholangitis)?","volume":"17","author":"Gisbert","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R106-31-20241201","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1478-3231.2007.01538.x","article-title":"Development of autoimmune hepatitis in primary biliary cirrhosis.","volume":"27","author":"Gossard","year":"2007","journal-title":"Liver Int"},{"key":"R107-31-20241201","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R108-31-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy.","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R109-31-20241201","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","article-title":"Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.","volume":"29","author":"Lohse","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R110-31-20241201","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/jhep.2002.30902","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.","volume":"35","author":"Joshi","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R111-31-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.","volume":"31","author":"Heurgue","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"R112-31-20241201","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: longterm outcomes.","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R113-31-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis autoimmune hepatitis overlap syndrome.","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"key":"R114-31-20241201","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(94)90829-X","article-title":"Autoimmune cholangiopathy: The result of consecutive primary biliary cirrhosis and autoimmune hepatitis?","volume":"107","author":"Colombato","year":"1994","journal-title":"Gastroenterology"},{"key":"R115-31-20241201","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1572-0241.2001.03562.x","article-title":"M Voigt. Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: a case report and review of the literature.","volume":"96","author":"Weyman","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R116-31-20241201","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.","volume":"44","author":"Poupon","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R117-31-20241201","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1478-3231.2004.0924.x","article-title":"Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis.","volume":"24","author":"Czaja","year":"2004","journal-title":"Liver Int"},{"key":"R118-31-20241201","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1440-1746.2006.04130.x","article-title":"Applicability of the IAIHG scoring system to the diagnosis of anitmitochondrialantiM2 seropositive variant form of autoimmune hepatitis.","volume":"21","author":"Farias","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R119-31-20241201","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1440-1746.2006.04434.x","article-title":"Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis.","volume":"21","author":"Nezu","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R120-31-20241201","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Longterm followup of antimitochondrial antibody positive autoimmune hepatitis.","volume":"48","author":"OBrien","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R121-31-20241201","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholicacid therapy for primary biliary cirrhosis: a metaanalysis.","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"R122-31-20241201","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and metaanalysis of randomized cinical trials using Bayesian approach as sensitivity analyses.","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R123-31-20241201","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary bilary cirrhosis.","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R124-31-20241201","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial.","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol"},{"key":"R125-31-20241201","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1046\/j.1365-2036.2000.00817.x","article-title":"Bioavailability of four ursodeoxycholic acid preparations.","volume":"14","author":"Williams","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R126-31-20241201","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterization of patients with a complete biochemical response to ursodeoxycholic acid.","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"key":"R127-31-20241201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"R128-31-20241201","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)61815-1","article-title":"Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis.","volume":"69","author":"Balan","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"R129-31-20241201","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxyholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R130-31-20241201","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004836-200308000-00018","article-title":"Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis.","volume":"37","author":"Siegel","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"R131-31-20241201","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0016-5085(86)90183-6","article-title":"Randomized trial of chlorambucil for primary biliary cirrhosis.","volume":"91","author":"Hoofnagle","year":"1986","journal-title":"Gastroenterology"},{"key":"R132-31-20241201","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM198504183121602","article-title":"Trial of penicillamine in advanced primary biliary cirrhosis.","volume":"312","author":"Dickson","year":"1985","journal-title":"N Engl J Med"},{"key":"R133-31-20241201","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/gut.26.2.114","article-title":"Double blind controlled trial of dpenicillamine in patients with primary biliary cirrhosis.","volume":"23","author":"Neuberger","year":"1985","journal-title":"Gut"},{"key":"R134-31-20241201","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment or primary biliary cirrhosis.","volume":"322","author":"Wiesner","year":"1990","journal-title":"N Engl J Med"},{"key":"R135-31-20241201","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","article-title":"Cyclosporine A treatment in primary biliary cirrhosis: results of a longterm placebo controlled trial.","volume":"104","author":"Lombard","year":"1993","journal-title":"Gastroenterology"},{"key":"R136-31-20241201","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0168-8278(92)90065-W","article-title":"A controlled trial of prenisolone treatment in primary biliary cirrhosis: Threeyear results.","volume":"15","author":"Mitchison","year":"1992","journal-title":"J Hepatol"},{"key":"R137-31-20241201","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial.","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"R138-31-20241201","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.mcg.0000177230.13770.4e","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R139-31-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Lowdose methotrexate is ineffective in primary biliary cirrhosis: longterm results of a placebocontrolled trial.","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastroenterology"},{"key":"R140-31-20241201","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198612043152304","article-title":"A prospective trial of cochicine for primary biliary cirrhosis.","volume":"215","author":"Kaplan","year":"1986","journal-title":"N Engl J Med"},{"key":"R141-31-20241201","first-page":"CD004481","article-title":"Colchicine for primary biliary cirrhosis.","volume":"2","author":"Gong","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"RU142-31-20241201","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1046\/j.1365-2036.2001.01018.x","article-title":"Tenyear combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a doubleblind, placebocontrolled trial on symptomatic patients.","volume":"15","author":"Battezzati","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"RU143-31-20241201","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Emerson SS, Flye NL. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.","volume":"42","author":"Combes","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R144-31-20241201","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/j.1572-0241.2001.05270.x","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a doubledosage worthwhile?","volume":"96","author":"Angulo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R145-31-20241201","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jhep.2000.18663","article-title":"Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.","volume":"32","author":"Angulo","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R146-31-20241201","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.20103","article-title":"A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: tenyear results.","volume":"39","author":"Kaplan","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R147-31-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.","volume":"31","author":"Angulo","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R148-31-20241201","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis.","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R149-31-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(99)02936-0","article-title":"Relief from profound fatigue associated with chronic liver disease by longterm ondansetron therapy.","volume":"354","author":"Jones","year":"1999","journal-title":"Lancet"},{"key":"R150-31-20241201","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/hep.20698","article-title":"A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.","volume":"41","author":"Theal","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R151-31-20241201","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, doubleblind controlled trial.","volume":"51","author":"Talwalkar","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R152-31-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.21230","article-title":"Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence.","volume":"44","author":"Newton","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R153-31-20241201","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa041292","article-title":"Modafinil for excessive sleepiness associated with shiftwork sleep disorder.","volume":"353","author":"Czeisler","year":"2005","journal-title":"N Engl J Med"},{"key":"R154-31-20241201","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-143-7-200510040-00024","article-title":"Modafanil for the treatment of fatigue in PBC.","volume":"143","author":"Kaplan","year":"2005","journal-title":"Ann Intern Med"},{"key":"R155-31-20241201","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis.","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R156-31-20241201","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis.","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"R157-31-20241201","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine.","volume":"265","author":"Van Itallie","year":"1961","journal-title":"N Engl J Med"},{"key":"R158-31-20241201","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasisassociated pruritus.","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R159-31-20241201","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","article-title":"Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis.","volume":"99","author":"Pares","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R160-31-20241201","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/00365520600610154","article-title":"Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus).","volume":"41","author":"Rifai","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"R161-31-20241201","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2006.08.008","article-title":"Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis.","volume":"45","author":"Pusl","year":"2006","journal-title":"J Hepatol"},{"key":"R162-31-20241201","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00544371","article-title":"Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis.","volume":"28","author":"Hoensch","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"R163-31-20241201","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a doubleblind, crossover, randomized trial.","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"R164-31-20241201","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"key":"R165-31-20241201","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin.","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"key":"R166-31-20241201","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a metaanalysis of prospective randomizedcontrolled trials.","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"key":"R167-31-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R168-31-20241201","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"key":"R169-31-20241201","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200002000-00023","article-title":"Rifampininduced slective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline.","volume":"20","author":"Markowitz","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R170-31-20241201","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2044.1989.tb09116.x","article-title":"The incidence of pruritus after epidural morphine.","volume":"44","author":"Ballantyne","year":"1989","journal-title":"Anaesthesia"},{"key":"R171-31-20241201","first-page":"367","article-title":"Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia.","volume":"71","author":"Abbound","year":"1990","journal-title":"Anesth Analg"},{"key":"R172-31-20241201","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/0016-5085(95)90709-2","article-title":"The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids.","volume":"108","author":"Bergasa","year":"1995","journal-title":"Gastroenterology"},{"key":"R173-31-20241201","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A doubleblind, randomized, controlled trial.","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"key":"R174-31-20241201","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.297.6662.1501","article-title":"Opioid peptides and primary biliary cirrhosis.","volume":"297","author":"Thornton","year":"1988","journal-title":"Br Med J"},{"key":"R175-31-20241201","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a doubleblind, placebocontrolled study.","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"key":"R176-31-20241201","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.","volume":"41","author":"Bergasa","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R177-31-20241201","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebocontrolled study.","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"key":"R178-31-20241201","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3748\/wjg.v12.i7.1125","article-title":"Effect of oral naltrexone on pruritus in cholestatic patients.","volume":"12","author":"MansourGhanaei","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R179-31-20241201","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","article-title":"Openlabel trial of oral nalmefene therapy for the pruritus of cholestasis.","volume":"27","author":"Bergasa","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R180-31-20241201","first-page":"1022","article-title":"Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease.","volume":"91","author":"Carson","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R181-31-20241201","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence.","volume":"345","author":"Krystal","year":"2001","journal-title":"N Engl J Med"},{"key":"R182-31-20241201","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(86)91196-7","article-title":"Naltrexone and hepatotoxicity.","volume":"i","author":"Mitchell","year":"1986","journal-title":"Lancet"},{"key":"R183-31-20241201","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0168-8278(97)80355-8","article-title":"Effect of liver cirrhosis on the systemic availability of naltrexone in humans.","volume":"27","author":"Bertolotti","year":"1997","journal-title":"J Hepatol"},{"key":"R184-31-20241201","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis.","volume":"125","author":"McRae","year":"2003","journal-title":"Gastroenterology"},{"key":"R185-31-20241201","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/14656566.9.4.645","article-title":"Pruritus and fatigue associated with liver disease: is there a role for ondansetron?","volume":"9","author":"Jones","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R186-31-20241201","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199405263302117","article-title":"Ondansetron for pruritus due to cholestasis.","volume":"21","author":"Raderer","year":"1994","journal-title":"N Engl J Med"},{"key":"R187-31-20241201","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0140-6736(93)91178-O","article-title":"Improvement of cholestatic pruritus by ondansetron.","volume":"341","author":"Schworer","year":"1993","journal-title":"Lancet"},{"key":"R188-31-20241201","first-page":"1196","article-title":"Ondansetron and pruritus in chronic liver disease: a controlled study.","volume":"54","author":"Jones","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"R189-31-20241201","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jpainsymman.2003.05.004","article-title":"Paroxetine in the treatment of severe nondermatological pruritus: a randomized, controlled trial.","volume":"26","author":"Zylicz","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"R190-31-20241201","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a firstline treatment for cholestatic pruritus.","volume":"45","author":"Mayo","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R191-31-20241201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients perspective.","volume":"88","author":"Rishe","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"R192-31-20241201","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000086667","article-title":"Antihistamines in dermatology.","volume":"18","author":"Greaves","year":"2005","journal-title":"Skin Pharmacol Physiol"},{"key":"R193-31-20241201","first-page":"224","article-title":"Liver Transplantation.","volume":"27","author":"Elias","year":"1993","journal-title":"J R Coll Physicians Lond"},{"key":"R194-31-20241201","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200111000-00022","article-title":"Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy.","volume":"13","author":"Neuberger","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R195-31-20241201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","article-title":"Topical ciclosporin in the treatment of ocular surface disorders.","volume":"89","author":"Tatlipinar","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R197-31-20241201","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0030-4220(06)80101-5","article-title":"Primary biliary cirrhosis. Sole presentation with rampant dental caries.","volume":"77","author":"Richards","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"R198-31-20241201","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12016-007-8008-3","article-title":"Conventional therapy of Sjogrens Syndrome.","volume":"32","author":"Mavragani","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"R199-31-20241201","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/PL00009532","article-title":"Primary biliary cirrhosis, sicca complex, and dysphagia.","volume":"12","author":"Mang","year":"1997","journal-title":"Dysphagia"},{"key":"R200-31-20241201","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.21749","article-title":"Increased prevalence of antimitochondrial antibodies in firstdegree relatives of patients with primary biliary cirrhosis.","volume":"46","author":"Lazaridis","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R201-31-20241201","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes.","volume":"26","author":"Jones","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R202-31-20241201","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.510290511","article-title":"Incidence of cancer in primary biliary cirrhosis: The Mayo experience.","volume":"29","author":"Nijhawan","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R203-31-20241201","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis.","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R204-31-20241201","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Practice Guideline Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma.","volume":"42","author":"Bruix","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R205-31-20241201","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R206-31-20241201","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","author":"Bressler","year":"2005","journal-title":"Gut"},{"key":"R207-31-20241201","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.12.10.830","article-title":"Portal hypertension in primary biliary cirrhosis.","volume":"12","author":"Kew","year":"1971","journal-title":"Gut"},{"key":"R208-31-20241201","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/01.pas.0000213286.65907.ea","article-title":"Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy.","volume":"30","author":"Abraham","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R209-31-20241201","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.","volume":"46","author":"GarciaTsao","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R210-31-20241201","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebocontrolled trial.","volume":"42","author":"Zein","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R211-31-20241201","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial.","volume":"33","author":"Lindor","year":"2000","journal-title":"J Hepatol"},{"key":"R212-31-20241201","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R213-31-20241201","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogenprogestin.","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R214-31-20241201","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","article-title":"Simvastatin in primary biliary cirrhosis: effects on serum lipds and distinct disease markers.","volume":"36","author":"Ritzel","year":"2002","journal-title":"J Hepatol"},{"key":"R215-31-20241201","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atheroscloertic risk: a systemic review.","volume":"194","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"key":"R216-31-20241201","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver.","volume":"41","author":"Chalasani","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R217-31-20241201","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","article-title":"Longterm fibrate treatment for PBC.","volume":"40","author":"Nakamuta","year":"2005","journal-title":"J Gastroenterol"},{"key":"R218-31-20241201","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(19)33896-X","article-title":"Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis.","volume":"57","author":"Schaffner","year":"1969","journal-title":"Gastroenterology"},{"key":"R219-31-20241201","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/BF01536666","article-title":"Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis.","volume":"33","author":"BaldoEnzi","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R220-31-20241201","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history.","volume":"9","author":"Sylvestre","year":"2003","journal-title":"Liver Transpl"},{"key":"R221-31-20241201","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/lt.21124","article-title":"Longterm survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.","volume":"13","author":"Charatcharoenwitthaya","year":"2007","journal-title":"Liver Transpl"},{"key":"R222-31-20241201","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/lt.20123","article-title":"Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.","volume":"10","author":"Neuberger","year":"2004","journal-title":"Liver Transpl"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22906","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200907000-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:43:45Z","timestamp":1733060625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200907000-00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":219,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22906","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}